In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.

$170,000 of NOVAVAX INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr.

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Bank of Montreal Can lowered its position in Novavax, Inc. (NASDAQ:NVAX – Free Report) by 99.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

The Trump administration is investing $500M in a project to develop "universal" vaccines that protect against multiple virus ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Markets were also boosted by the prospect of a quieter geopolitical environment, as the US attempts to smooth the wrinkles in ...

The U.S. Food and Drug Administration (FDA) is planning to require all new vaccines to undergo placebo-controlled trials ...